Serum haptoglobin, CA 125 and interleukin 6 levels in malignant and non-malignant tumors of the ovary.

In sera of women with malignant and non-malignant ovarian tumors, concentrations of the following proteins were determined: haptoglobin, measured by the reactions either with hemoglobin (Hp-Hb) or with concanavalin A (Hp-Con A), CA 125 antigen and interleukin 6 (IL-6). Besides preoperative data, obtained from all the patients and the group of healthy women, in the patients with ovarian cancer (III/IV FIGO stages) effects of administration of cytostatics were measured by monitoring changes in the levels of the examined parameters through the course of the therapy. All the results were submitted to statistical evaluation which showed differences and correlations among definite groups (normal/non-malignant, normal/cancers, non-malignant/cancers). Similar results were obtained for Hp-Hb and CA 125 determination. Moreover, a correlation between haptoglobin level and age was found. Patterns of monitoring revealed a surprising absence of Hp-Con A interaction in some cases.

[1]  A. van Dalen,et al.  TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms. , 1997, Anticancer research.

[2]  W. Dobryszycka,et al.  Biological functions of haptoglobin--new pieces to an old puzzle. , 1997, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[3]  H. Tilg,et al.  IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. , 1997, Immunology today.

[4]  P. Stieber,et al.  Clinical significance of the tumour markers CA 125 II and CA 72‐4 in ovarian carcinoma , 1996, International journal of cancer.

[5]  I. Barillot,et al.  Valeur pronostique de la demi-vie initiale du CA 125 mesurée au cours de la chimiothérapie d'induction chez 62 patientes porteuses de tumeur épithéliale ovarienne stade III ou IV. , 1996 .

[6]  F. Zullo,et al.  A risk model for ovarian carcinoma patients using CA 125: Time to normalization renders second‐look laparotomy redundant , 1996, Cancer.

[7]  R. Bast,et al.  Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection , 1995, Cancer.

[8]  P. Schwartz,et al.  Is early detection of ovarian cancer possible? , 1995, Annals of medicine.

[9]  P. Sevelda,et al.  Preoperative CA 125: An Independent Prognostic Factor in Patients With Stage I Epithelial Ovarian Cancer , 1995, Obstetrics and gynecology.

[10]  M. McGuckin,et al.  Predictive value of the combination of serum markers, CA125, CASA and TPS in ovarian cancer , 1994, International Journal of Gynecologic Cancer.

[11]  W. Droegemueller.  Screening for ovarian carcinoma: hopeful and wishful thinking. , 1994, American journal of obstetrics and gynecology.

[12]  S. Rubin,et al.  Interleukin‐6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer , 1994, Cancer.

[13]  J. Gauldie,et al.  The acute phase response. , 1994, Immunology today.

[14]  J. Stuart,et al.  Effect of patient age on tests of the acute-phase response. , 1993, Archives of pathology & laboratory medicine.

[15]  N. Bander,et al.  High IL‐6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer , 1993, British journal of haematology.

[16]  H. Toda,et al.  Circulating interleukin 6 as a useful marker for predicting postoperative complications. , 1992, Cytokine.

[17]  J. Berek,et al.  Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. , 1991, American journal of obstetrics and gynecology.

[18]  R. Bast,et al.  Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.

[19]  P. Kenemans,et al.  Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. , 1996, American journal of obstetrics and gynecology.

[20]  M. Onsrud,et al.  Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer. , 1996, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[21]  S. Narayanan.  Laboratory markers as an index of aging. , 1996, Annals of clinical and laboratory science.

[22]  M. Suresh.  Classification of tumor markers. , 1996, Anticancer research.

[23]  W. Dobryszycka,et al.  Measurements of Haptoglobin by the Reaction with Concanavalin A in Sera of Patients with Ovarian Tumours , 1995, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[24]  M. Onsrud,et al.  Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma. , 1994, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[25]  G. Peters,et al.  Changes in glycosylation of L1210 cells after exposure to various antimetabolites. , 1993, European journal of cancer.

[26]  T. Hirano.  Interleukin 6 and autoimmunity and plasma cell neoplasias. , 1992, Research in immunology.

[27]  J. Zuwała-Jagiełło,et al.  Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma. , 1991, Archivum immunologiae et therapiae experimentalis.

[28]  R. Bast,et al.  CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. , 1989, Acta oncologica.

[29]  J. Morote Robles.  [What...about tumor markers]. , 1988, Actas urologicas espanolas.

[30]  W. Bezwoda.  Treatment of advanced ovarian cancer: a randomised trial comparing adriamycin or 4'epi-adriamycin in combination with cisplatin and cyclophosphamide. , 1986, Medical and pediatric oncology.

[31]  M. Warwas,et al.  Haptoglobin and proteinase inhibitors in the blood serum of women with inflammatory, benign and neoplastic lesions of the ovary. , 1986, Neoplasma.

[32]  W. Dobryszycka,et al.  Clinical usefulness of serum acute-phase reactants in patients with ovarian tumors. , 1981, Neoplasma.